The Acquisition of Worldwide Rights to Vecoxan®
We are pleased to announce that we have made an exciting addition to our ruminant parasiticide portfolio. We have completed the acquisition of worldwide rights to VECOXAN® (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs.
This acquisition will bolster our portfolio offerings for parasite control and protection, which are paramount to ensuring the overall health and well-being of ruminants. With VECOXAN, we are now equipped to offer farmers and producers a product that will ensure the protection of their youngstock. This is an important differentiator, as the first months of calves’ and lambs’ lives are critical to their future health. Products like this one – coupled with our extensive portfolio and advanced digital and diagnostic solutions to manage the welfare of animals – are instrumental in helping us advance the health and well-being of animals and those who care for them.
We are eager to see the success of our teams with VECOXAN. Also, as the global demand for protein increases, we take pride in our company’s ongoing efforts to provide comprehensive solutions that will support a safe, sustainable, transparent food supply. This is yet another example of our dedication to ensuring The Science of Healthier Animals® as we further our strategic efforts to pioneer science and technology.